Kiniksa Pharmaceuticals, Ltd. KNSA 深 滬
已收盤 05-08 16:00:00 美东时间
58.60
+1.670
+2.93%
華盛通- 最 高58.85
- 今 開57.06
- 成交量 39.43万股
- 最 低 56.83
- 昨 收 56.93
- 總市值 45.09亿
- 52周最高 58.85
- 市盈率 靜 78.44
- 換手率 0.51%
- 52周最低 25.70
- 委 比 64.38%
- 總股本 7693.80万
- 歷史最高 58.85
- 量 比 0.52
- 振 幅 3.55%
- 歷史最低 5.01
- 每 手 1
- 風險率 7.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor
Kiniksa Pharmaceuticals ( ($KNSA) ) has shared an announcement. On April 30, 20...
05-02 05:55
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
美股牛股 | 26财年Q2营收翻倍！新美亚电子大涨近15%；美国健康保险巨头康西哥大涨14%
26财年Q2营收翻倍！新美亚电子大涨近15%；美国健康保险巨头康西哥涨14%，Q1盈利大超市场预期>>
04-29 16:13
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $71
Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $58 to $71.
04-29 02:02
CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
04-28 22:06
Kiniksa Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Kiniksa Pharmaceuticals (NASDAQ:KNSA) released first-quarter financial results ...
04-28 21:33
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $900.000M-$920.000M to $930.000M-$945.000M vs $913.245M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $900.000 million-$920.000 million to $930.000 million-$945.000 million vs $913.245 million estimate.
04-28 19:45
Kiniksa Pharmaceuticals Q1 EPS $0.27 Beats $0.19 Estimate, Sales $214.300M Beat $206.091M Estimate
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.19 by 42.11 percent. This is a 145.45 percent increase over earnings of $0.11 per share
04-28 19:42
Earnings Scheduled For April 28, 2026
Companies Reporting Before The Bell • LGI Homes (NASDAQ:LGIH) is likely to repo...
04-28 19:11
